- Canada
- /
- Professional Services
- /
- CNSX:BLAB
Britannia Life Sciences Second Quarter 2024 Earnings: EPS: CA$0.004 (vs CA$0.007 in 2Q 2023)
Britannia Life Sciences (CSE:BLAB) Second Quarter 2024 Results
Key Financial Results
- Revenue: CA$2.07m (up 30% from 2Q 2023).
- Net income: CA$724.2k (down 33% from 2Q 2023).
- Profit margin: 35% (down from 68% in 2Q 2023).
- EPS: CA$0.004 (down from CA$0.007 in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Britannia Life Sciences' share price is broadly unchanged from a week ago.
Risk Analysis
It's necessary to consider the ever-present spectre of investment risk. We've identified 4 warning signs with Britannia Life Sciences (at least 2 which make us uncomfortable), and understanding these should be part of your investment process.
Valuation is complex, but we're here to simplify it.
Discover if Britannia Life Sciences might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About CNSX:BLAB
Britannia Life Sciences
Engages in the provision of product testing, safety assessment, and compliance services primarily to the cosmetics, consumer packaged and household goods, and nutraceutical industries in the United Kingdom and internationally.
Good value with imperfect balance sheet.